New Venture: AdvocateMH Garners Seed Investment with Morningside's Backing

Dr. David Mou, having recently left the CEO position at Cerebral, a mental health startup that has faced challenges, is embarking on a fresh business journey. His new initiative, AdvocateMH, has successfully secured initial funding through Morningside, a private equity and venture capital firm, as revealed to Business Insider.

AdvocateMH is focused on assisting individuals needing mental health care by linking them with appropriate resources, though the precise funding amount remains undisclosed by Mou. This marks the fourth startup backed by venture capital for Mou, who exited Cerebral in December—once looked up to as a SoftBank-funded entity worth $4.8 billion.

Mou’s exit follows a tumultuous period at Cerebral marked by sizable settlements with federal and state authorities concerning its drug prescription practices, alongside mounting investor disputes.

In the year 2022, Cerebral was criticized for its handling of medication prescriptions including Adderall. After U.S. Department of Justice inquiries, a 2024 investor lawsuit highlighted Cerebral's worsening financial health. In light of this, Mou is spearheading AdvocateMH with a fresh strategy towards mental health care and venture financing.

Shifting Tactics in Mental Health advocacy

According to both Mou and Dr. Thomas Insel, co-founder and president of AdvocateMH, a unique approach is underway. The goal is to introduce an advocate for those needing mental health services, available via referrals from primary care providers or after engaging with crisis resources like suicide hotlines.

Established as a public interest corporation earlier this year in January, AdvocateMH is still in its conceptual phase. The company aims to differentiate itself by forgoing the typical revenue model employed by many companies today, which involves taking a percentage of referral volumes, described by Mou as fostering 'undesirable incentives.'

Innovation and Technology Integration

AdvocateMH strives to improve patient care by employing licensed clinical social workers to evaluate clients and decide on further care steps, intending to integrate AI tools for enhancing clinical decisions. Mou, alongside Insel, believes AI will amplify clinician efficacy rather than replace professionals, providing a competitive advantage to those who embrace technology.

Reflecting on his tenure at Cerebral, where he started as the chief medical officer in 2021, Mou acknowledges the importance of early and strategic clinician leadership in startup ventures like AdvocateMH. This insight now guides the company’s operational and strategic blueprint, amidst plans to update on its funding round and board advisors soon.